Zevra to face FDA ad­comm in Au­gust over pre­vi­ous­ly re­ject­ed rare dis­ease drug

The FDA’s re­cent­ly cre­at­ed Ge­net­ic Meta­bol­ic Dis­eases Ad­vi­so­ry Com­mit­tee will meet on Aug. 2 to re­view Zevra Ther­a­peu­tics’ ari­mo­clo­mol as a treat­ment for the rare …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.